Literature DB >> 21605982

Beneficial effects of l-leucine and l-valine on arrhythmias, hemodynamics and myocardial morphology in rats.

Katarzyna Mitręga1, Michał Zorniak, Benoy Varghese, Dariusz Lange, Jerzy Nożynski, Maurycy Porc, Szymon Białka, Tadeusz F Krzemiński.   

Abstract

Branched chain amino acids (BCAA) have been shown to have a general protective effect on the heart in different animal models as well as in humans. However, so far no attempt has been made to specifically elucidate their influence on arrhythmias. Our study was performed to evaluate whether an infusion of either l-leucine or l-valine in a dose of 1mgkg(-1)h(-1) 10min before a 7-min period of left anterior descending artery occlusion followed by 15min of reperfusion, had an effect on arrhythmias measured during the reperfusion phase in the ischemia- and reperfusion-induced arrhythmias model in rats in vivo. The effect of the infusion of these substances on mean arterial blood pressure was monitored throughout the experiment. Both of the tested amino acids exhibited significant antiarrhythmic properties. l-Leucine reduced the duration of ventricular fibrillation (P<0.05) and l-valine decreased the duration of ventricular fibrillation (P<0.001) and ventricular tachycardia (P<0.05). The two amino acids were generally hypotensive. l-Valine lowered blood pressure in all phases of the experiment (P<0.05) while l-leucine lowered this parameter mainly towards the end of occlusion and reperfusion (P<0.05). In addition, 30min infusion of the amino acids in the used dose did not produce any apparent adverse histological changes that were remarkably different from control. In summary, the results of our study suggest that l-leucine and l-valine in the dose that was used attenuates arrhythmias and are hypotensive in their influence. Our findings lend support to the many ongoing investigations into the benefit of the application of l-leucine and l-valine in cardiology like their addition to cardioplegic solutions. 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21605982     DOI: 10.1016/j.phrs.2011.04.011

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  6 in total

1.  Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2.

Authors:  Wouter De Haes; Lotte Frooninckx; Roel Van Assche; Arne Smolders; Geert Depuydt; Johan Billen; Bart P Braeckman; Liliane Schoofs; Liesbet Temmerman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-02       Impact factor: 11.205

2.  Protective role of deoxyschizandrin and schisantherin A against myocardial ischemia-reperfusion injury in rats.

Authors:  Ruimiao Chang; Yong Li; Xingxin Yang; Yuan Yue; Lili Dou; Yanwei Wang; Weifang Zhang; Xiaoni Li
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

3.  Impact of leucine supplementation on exercise training induced anti-cardiac remodeling effect in heart failure mice.

Authors:  Wilson Max Almeida Monteiro de Moraes; Thaís Plasti Melara; Pamella Ramona Moraes de Souza; Fabiana de Salvi Guimarães; Luiz Henrique Marchesi Bozi; Patricia Chakur Brum; Alessandra Medeiros
Journal:  Nutrients       Date:  2015-05-15       Impact factor: 5.717

4.  Serum Levels of Branched Chain Amino Acids Predict Duration of Cardiovascular Organ Failure in Septic Shock.

Authors:  Michael A Puskarich; Cora McHugh; Thomas L Flott; Alla Karnovsky; Alan E Jones; Kathleen A Stringer
Journal:  Shock       Date:  2021-07-01       Impact factor: 3.533

5.  Differential effects of furnidipines' metabolites on reperfusion-induced arrhythmias in rats in vivo.

Authors:  Katarzyna A Mitrega; Maurycy Porc; Tadeusz F Krzeminski
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

6.  Characterization and bioactivity of novel calcium antagonists - N-methoxy-benzyl haloperidol quaternary ammonium salt.

Authors:  Yi-Cun Chen; Wei Zhu; Shu-Ping Zhong; Fu-Chun Zheng; Fen-Fei Gao; Yan-Mei Zhang; Han Xu; Yan-Shan Zheng; Gang-Gang Shi
Journal:  Oncotarget       Date:  2015-12-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.